Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Current Leases (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Current Leases for 6 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 15.92% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a 15.92% increase, with the full-year FY2025 number at $2.2 million, up 15.92% from a year prior.
  • Current Leases was $2.2 million for Q4 2025 at PROCEPT BioRobotics, up from $2.1 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $3.0 million in Q1 2023 to a low of $1.7 million in Q4 2023.
  • A 5-year average of $2.1 million and a median of $2.1 million in 2021 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: skyrocketed 37.46% in 2023, then plummeted 43.26% in 2024.
  • PROCEPT BioRobotics' Current Leases stood at $2.1 million in 2021, then rose by 1.14% to $2.1 million in 2022, then dropped by 20.95% to $1.7 million in 2023, then grew by 13.49% to $1.9 million in 2024, then rose by 15.92% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Current Leases are $2.2 million (Q4 2025), $2.1 million (Q3 2025), and $2.1 million (Q2 2025).